Loading...
•
Mar 31, 2020
Cabaletta Bio Q1 2020 Earnings Report
Cabaletta Bio announced financial results for the first quarter ended March 31, 2020.
Key Takeaways
Cabaletta Bio reported first quarter 2020 financial results, with research and development expenses at $4.6 million and general and administrative expenses at $3.3 million. Cash and cash equivalents totaled $131.0 million as of March 31, 2020.
FDA granted Fast Track Designation to DSG3-CAART for mucosal pemphigus vulgaris (mPV).
Phase 1 DesCAARTesTM trial is ready to launch pending lifting of COVID-19 related clinical trial activity restrictions.
IND-enabling studies for MuSK-CAART are planned to be initiated in 2020.
Cash and cash equivalents are expected to fund operating plan through at least the third quarter of 2022.
Forward Guidance
Cabaletta Bio expects that its current cash and cash equivalents will enable it to fund its operating plan through at least the third quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...